• Male or female, aged ≥ 18 years

• Patients expressing HLA-A2 phenotype in blood by pre-screening central laboratory

• Patients with histologically or cytologically squamous or non-squamous documented NSCLC, metastatic stage at study entry, not eligible for definite surgery or radiation, without EGFR, ALK and ROS1 gene alterations eligible for targeted therapy; other sensitizing mutations known to be immunosensitive are eligible in case of lack of local access to targeted therapy (i.e.; KRAS G12C and BRAF mutations) after Sponsor's agreement

• Patients with secondary resistance to ICI;